GovChime
Notice ID: eb7e8e8c431d42a396fc15f7bb3eb17eCombined Synopsis/SolicitationArchived

Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus

Archived on October 2, 2025. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
11:00 AM PDT
Posted
September 16, 2025
Notice type
Combined Synopsis/Solicitation
Set-aside
No Set aside used
NAICS
325413: In-Vitro Diagnostic Substance Manufacturing
Agency
Department of WarDepartment of the Army

Notice details

Office
W40M MRCO PACIFIC
Place of performance
Tacoma
Last updated
Nov 8, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
W81K0225QA107
Notice ID
eb7e8e8c431d42a396fc15f7bb3eb17e

Description

THIS NOTICE OF INTENT IS NOT A REQUEST FOR QUOTES. A DETERMINATION NOT TO COMPETE THE PROPOSED PROCUREMENT BASED UPON RESPONSES TOTHIS NOTICE IS SOLELY WITHIN THE DISCRETION OF THE GOVERNMENT. Medical Readiness Contracting Office - Pacific hereby provides notice of its intent to award a sole-source, firm fixed price contract under the authority of FAR 13.106-1(b)(1). As a result, the Government intends to award directly to Qiagen, LLC, Germantown, MD, CAGE 01QT0, in accordance with FAR 13.106-1(b)(1). This requirement is expected to be an indefinite delivery indefinite quantity (IDIQ) contract for a 5-year ordering period. This requirement is for the procurement of QuantiFERON TB Gold-Plus assay reagents for running QuantiFERON TB-Gold Plus for the detection of Mycobacterium Tuberculosis immune responses by enzyme immunoassay (EIA) at Madigan Army Medical Center (MAMC). The government currently utilizes the DiaSorin LIAISON XL analyzer at MAMC to detect latent Mycobacterium tuberculosis infection. QuantiFERON TB Gold-Plus assays are the only FDA-cleared interferon-gamma release assays that can be used on the analyzer at MAMC without the need to purchase and install additional instrumentation for operability that would only result in partial automation. It would also be necessary to obtain additional physical workspace to accommodate the added system, which MAMC does not have. Therefore, only the QuantiFERON-TB Gold Plus reagents can meet the governments requirement to ensure continuity of operations, maintain required testing capacity, and meet DHA reference laboratory obligations. The attached salient characteristics detail the requirements of this anticipated contract action. Market Research has demonstrated that the intended awardee is the only business that is able to meet the requirements. THIS NOTICE OF INTENT IS NOT A REQUEST FOR QUOTES; no solicitation or RFQ will be forthcoming. Any firm that believes it can provide the stated supplies can provide supporting documents demonstrating their capabilities and certifications. Interested parties may identify their interest and capability to respond to this requirement no later than Wednesday, 17 September 2025 at 11:00 AM Pacific Time. All documents submitted will not be returned. Responses received may be used for future acquisitions. All interested parties shall submit clear and convincing documentation demonstrating their capabilities to satisfy the requirements contained within the attached Statement of Work. The capability documentation should include general information and technical background describing in detail the prospective contractor's capabilities and experience that will demonstrate the ability to support these requirements. Interested parties are encouraged to furnish information by email only with subject line stating - RESPONSE TO INTENT TO SOLE SOURCE FOR W81K0225QA107. Information can be sent to Brittany Chartier at brittany.n.chartier.civ@health.mil. No telephone or facsimile requests will be accepted. This procurement will be prepared in accordance with FAR Part 13, Simplified Acquisition Procedures. Medical Readiness Contracting Office - Pacific will NOT be responsible for any costs incurred by interested parties in responding to this notice of intent. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

Files (1)

  • Salient Characteristics Qiagen LIAISON QuantiFERON TB Gold Plus and Control.pdf

    92 KBAdded in Combined Synopsis/Solicitation version 7Posted
    Download

Lifecycle

  1. 3
    Version 3Sources SoughtArchived

    Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus

    Notice 072597f1ce57452db4f8f0264bfd6daa on SAM.gov

  2. 7
    Version 7Combined Synopsis/SolicitationArchivedCurrent

    Type changed from Sources Sought to Combined Synopsis/Solicitation

    Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus

    Notice eb7e8e8c431d42a396fc15f7bb3eb17e on SAM.gov

  3. 9
    Version 9Award NoticeArchived

    Type changed from Combined Synopsis/Solicitation to Award Notice

    Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus

    Notice 3e174cfc24014b4e9e68a1fc53bc8bb5 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

W81K0225QA107

Archive Date

Oct 2, 2025